Medtronic's Jason Fontana offers an update on next-generation Symplicity Spyral devices, procedures and a new feature they're ...

Analysts are optimistic about Medtronic (MDT) after the Centers for Medicare and Medicaid Services (CMS) proposed to cover ...

Catheter-based sympathetic renal denervation (RDN) therapy is an exciting and promising new treatment strategy, with potential to revolutionize the current treatment paradigm in this group of ...

He added that “renal denervation offers an attractive approach for the treatment of comorbidities which are often associated with sympathetic nervous system overactivity,” like atrial fibrillation (AF ...

About the Paradise Ultrasound Renal Denervation System The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN ...

Endovascular ultrasound for renal sympathetic denervation appears to be a safe and effective treatment option among patients with therapy-resistant hypertension who do not respond to ...

The United States Food and Drug Administration, in 2023, approved renal denervation—a catheter-based procedure that ablates the renal sympathetic nerves—as an adjunctive treatment for patients ...

Renal denervation with the Spyral resulted in a significant but modest 3.9-mm Hg ASBP reduction in the SPYRAL HTN-OFF MED trial of people who had their medications withdrawn in the first 3 months ...

Three small needles are pushed out from inside the device. They go through the artery wall into the fluid-filled space that surrounds it (perivascular). The needles release small amounts of alcohol ...

The pathophysiology of essential hypertension is complex and multifactorial. It is thought that abnormal renal excretory function plays a central role in the initiation, development and ...